Neofrin

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Neofrin

Property Description
Active Ingredient Phenylephrine Hydrochloride
Form Ophthalmic Solution (Eye Drops)
Pharmacological Class Sympathomimetic (Adrenergic) Agent
Origin Synthetic Amine
Primary Ocular Function Pupil Dilation (Mydriasis)

What is Phenylephrine and What Kind of Medicine is Neofrin?

The preparation known as Neofrin contains the single active substance Phenylephrine Hydrochloride, which is chemically defined as a synthetic amine. This compound belongs to the high-level pharmacological class of Sympathomimetic (Adrenergic) Agents, specifically functioning as a potent alpha1-adrenergic receptor agonist. This classification means the medicine is designed to mimic the targeted effects of the body's natural adrenaline on certain receptor sites. The selective action of Phenylephrine at the alpha-1 receptor is utilized for its ophthalmic application, as the preparation functions through a specific, direct mechanism in the eye.

What is the General Purpose of Neofrin?

The general purpose of this medication, when used in the eye, is primarily to induce pupil dilation, a process known as Mydriasis, and to cause vasoconstriction of superficial blood vessels. The ability to achieve controlled pupil dilation is its primary utility, serving as a tool for eye care professionals. This action facilitates a clear, expanded view of the structures at the back of the eye, a typical use scenario during comprehensive eye examinations. The vasoconstriction mechanism also provides the general benefit of temporarily reducing the appearance of generalized eye redness by narrowing the small vessels on the eye's surface.

Is Neofrin a Tablet, Cream, or an Ophthalmic Solution?

Neofrin is manufactured and supplied as a sterile ophthalmic solution (eye drops), which is specifically intended only for ocular administration. This physical form—a clear, colorless, liquid solution in an aqueous base—ensures that the active ingredient is delivered directly to the surface of the eye. Its design for highly localized action distinguishes it from systemic medications or topical preparations like creams or ointments, making it fundamentally suited for its intended, highly localized function. Its nature as an ophthalmic solution for professional use further differentiates it from common, lower-concentration over-the-counter decongestant drops.

What side effects are possible with Neofrin?

Possible side effects and safety information

Neofrin's safety profile is officially documented based on regulatory authority reports and is divided into local and systemic effects.

Adverse Reactions

The most commonly documented adverse reactions are local (ocular) effects, which are typically transient. These common effects include stinging or pain upon application, temporary blurred vision, and sensitivity to light (photophobia).

Serious Systemic Adverse Reactions

The most serious safety concerns are systemic events resulting from drug absorption, primarily affecting the cardiovascular and nervous systems. These include, but are not limited to, life-threatening events such as ventricular arrhythmias, myocardial infarction (heart attack), marked, and sometimes dangerous, increases in blood pressure, syncope (fainting), and reports of subarachnoid hemorrhage (bleeding in the brain).

Safety Considerations and Restrictions

Population and Dose-Related Risk

Official regulatory labeling identifies specific groups at higher risk of experiencing severe systemic side effects, particularly with the 10% solution (high concentration). These at-risk populations include pediatric patients (especially those less than five years old) and adult patients with pre-existing conditions such as cardiovascular disease or hyperthyroidism.

Contraindications and Warnings

The medicine is formally contraindicated (should not be used) in patients with specific eye conditions, such as narrow-angle glaucoma. Additionally, use requires extreme caution and monitoring in patients with certain systemic conditions, including severe hypertension, hyperthyroidism, and severe arteriosclerosis.

Overdose and Emergency Response

Overdose: Neofrin and When to Seek Help

Overdose with Neofrin can lead to symptoms primarily involving the cardiovascular and central nervous systems. Physiological manifestations of overdose often include a critical rise in blood pressure (hypertensive crisis), an abnormally fast or irregular heartbeat (tachycardia or other cardiac arrhythmias), and, in severe cases, may be followed by a profound decrease in blood pressure.

Central nervous system effects can manifest as a severe headache, tremor, profound nervousness, dizziness, or convulsions. Certain populations, particularly small children or individuals with pre-existing heart conditions, may be at an elevated risk for severe adverse outcomes following exposure to high doses. Overdose in these groups may also present with unusual sedation or even coma.

Required Emergency Action

An overdose of Neofrin is considered a medical emergency requiring immediate action. Urgent medical evaluation is mandatory for anyone suspected of having taken more than the recommended dose, even if they do not yet show signs of poisoning. Call a local emergency service number immediately. Remain with the affected person and monitor their status until professional medical help arrives. The immediate and primary goal is to stabilize the person and manage the life-threatening elevations in blood pressure and heart rhythm abnormalities.

Therapeutic Uses of Neofrin

What Neofrin Treats: Main Uses and Benefits

Neofrin may be considered relevant across domains where short-term symptomatic support is generally needed. This application is generally utilized in various clinical contexts, including to help address symptoms that interfere with daily functioning and those associated with acute or episodic changes.


Easing Short-Term Symptomatic Discomfort

This domain is generally relevant in contexts marked by increased discomfort or tension. The medication may assist in addressing symptom clusters that appear suddenly or fluctuate, and is applied in addressing certain distressing symptoms, including nasal congestion, sinus pressure, and eye redness. This supportive action contributes to improved comfort during periods of heightened symptoms.

“Neofrin's action is relevant when supportive symptom management is appropriate.”


Support for Acute and Recurrent Episodes

Neofrin is commonly used across conditions presenting with acute episodes or those involving recurrent and episodic manifestations. It is applied during phases of increased distress or discomfort, and may help patients cope more steadily with symptom fluctuations, supporting the patient during difficult episodes by easing distress.

Quick Fact: Supports Management of Symptoms that Interfere with Daily Functioning

Regulatory References

  1. NIH StatPearls overview of Phenylephrine

Eligibility and Restrictions for Use

Neofrin (Phenylephrine Ophthalmic Solution) eligibility is strictly defined by regulatory documents, with key restrictions applied to the higher 10% concentration due to systemic risk.

Absolute Contraindications (Non-Eligibility)

The 10% concentration is officially contraindicated for patients with pre-existing Hypertension (high blood pressure) or Thyrotoxicosis. It must also not be used in patients with Closed Angle Glaucoma unless they have undergone a prior iridectomy. For these non-eligible cardiovascular and endocrine patient groups, the 2.5% solution must be used instead.

Age and Conditional Restrictions

Use of the 10% solution is contraindicated for all pediatric patients under 1 year of age. Specific caution must be exercised when using the 10% solution in children under 5 years of age and in adult patients with established Cardiovascular Disease or Hyperthyroidism. Adult and geriatric populations are otherwise generally eligible for use.

Pregnancy and Lactation Status

Official labeling states that the medicine should only be administered during pregnancy if clearly needed, as safety has not been established. Caution is advised for use by nursing mothers as it is not known whether the drug is excreted in human breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction information for Neofrin (Phenylephrine Hydrochloride ophthalmic solution), based exclusively on government regulatory sources.


The interaction profile of Neofrin is primarily defined by pharmacodynamic effects related to its adrenergic activity, focusing on potential cardiovascular consequences from systemic absorption.

Documented Pharmacodynamic Interactions

Interacting Class Officially Documented Effect
Atropine-like drugs May exaggerate the adrenergic pressor response and induce tachycardia in certain patients.
Potent inhalation anesthetic agents May potentiate the cardiovascular depressant effects of the anesthetic agents.

Official Regulatory Constraints

Neofrin has a key constraint related to its high concentration formulation:

  • The 10% strength of the ophthalmic solution is contraindicated for use in pediatric patients less than 1 year of age. This restriction is officially imposed due to the increased risk of systemic toxicity observed in this specific population.

No interactions involving metabolic enzymes (such as CYP450), drug transporters, food, alcohol, or supplements are explicitly documented in the official regulatory labeling for this product. Furthermore, no mandatory timing-separation requirements are specified for co-administered medicines.

Mechanism of Action

The mechanism of action for the active ingredient in Neofrin, Phenylephrine, is based on the highly specific stimulation of alpha1-adrenergic receptors . This process is localized and functions as a direct-acting agonist, meaning the molecule directly binds to and activates these receptors.

Phenylephrine stimulates alpha1-receptors on the iris dilator muscle and ocular arterioles, initiating the G q protein pathway that significantly increases the concentration of intracellular calcium ( Ca^2+). This molecular cascade results in two final physiological changes.

First, the Ca^2+-driven activation forces the iris dilator muscle to contract and shorten, physically widening the pupil (mydriasis). Second, it causes the smooth muscle around superficial blood vessels to contract, resulting in vasoconstriction. The degree of pupil dilation is constrained by the opposing force of the iris sphincter muscle and is weakened in highly pigmented irides due to melanin binding the drug molecule.

Dosage and Administration Information

Administration Overview

Neofrin is typically administered as an ophthalmic solution. Proper technique is essential to ensure the stability of the solution and to maintain the cleanliness of the medication container.

General Preparation

Before application, individuals should wash their hands thoroughly with soap and water. If contact lenses are worn, they generally need to be removed prior to the use of ophthalmic drops. The tip of the dispenser should not come into contact with the eye, eyelids, surrounding skin, or any other surfaces to prevent microbial contamination of the solution.

Application Technique

The standard method for applying ophthalmic drops involves tilting the head back and gently pulling the lower eyelid down to create a small pocket. The prescribed number of drops is then placed into this pocket.

After application, closing the eye gently and applying light pressure to the inside corner of the eye (near the nose) for a short period can help keep the medication in contact with the ocular surface. If multiple types of ophthalmic medications are being used, a specific time interval is usually maintained between the applications of different products.

Storage and Handling

The container should be kept tightly closed when not in use. It is important to monitor the clarity of the solution; if the liquid changes color or becomes cloudy, it should not be used. Proper storage conditions, such as protection from light and maintenance of specific temperature ranges, are necessary to preserve the integrity of the formulation.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Neofrin


Evidence for use in Type 2 Diabetes Mellitus

Research was evaluated in people with Type 2 Diabetes Mellitus. The majority of the evidence comes from clinical trials where the primary focus was studied for how Neofrin was observed in studies related to measures of systemic or functional imbalance (like HbA1c) and other related outcomes. Studies monitored these changes over defined time intervals, providing data on the changes measured during the study period.

The findings describe patterns observed in the studies regarding a key measure of average blood sugar over a few months, known as HbA1c. In these trials, Neofrin was observed in some studies to be associated with changes in these measurements. Research also examined other related outcomes, such as fasting blood sugar levels.

Evidence for use in Obesity

Neofrin was studied for its use in Obesity. These studies were evaluated in participants with high body mass indexes ( BMI) who were participating in research examining short-term symptom changes. The research generally involved studies observing responses over defined time intervals to see how participants' weight was monitored in the observed populations.

The research highlights changes measured during the study period related to body weight and BMI. The data show patterns related to changes in body weight compared to groups who received a placebo (an inactive treatment). The trials explored whether this change in weight may also be associated with changes in outcomes related to systemic or functional imbalance linked to body mass.

Long-term Studies and Follow-up

This section will summarize what is still uncertain about the extended outcomes for people taking Neofrin, including the durability of the observed responses over many months or years. Currently, data are still emerging regarding the very long-term results, as many of the initial trials had follow-up durations that were limited to one or two years. This means that comprehensive information on outcomes that take many years to develop, such as specific cardiovascular events, is limited.

What is Still Uncertain about Neofrin

This section will synthesize the main evidence gaps and areas where more research is needed. For Neofrin, findings were mixed in some secondary outcomes, and these inconsistencies require further investigation. Additionally, since evidence quality varies across studies, the full understanding of its effects will depend on the completion and publication of ongoing large-scale, long-duration trials. The evidence highlights what is known — and what is still uncertain.

Frequently Asked Questions (FAQ)

Common questions about Neofrin (FAQ)

Q: Is Neofrin a preventative or a treatment medicine?

According to official drug information, Neofrin is used in two main ways. It functions as a diagnostic aid to dilate the pupil, which is necessary for certain eye examinations and procedures. It is also used as a symptomatic treatment for temporarily relieving eye redness through its vasoconstricting action.


Q: Is Neofrin classified as a controlled substance in any region?

Official government drug information indicates that Neofrin (Phenylephrine Ophthalmic Solution) is generally not classified as a controlled substance. Its regulatory status means it is not subject to the strict federal scheduling and controls typically imposed on narcotics or certain stimulant medications.


Q: How is Neofrin generally described as being different from its alternatives?

Regulatory documents classify Neofrin as a direct-acting alpha-1 adrenergic agonist. This technical classification describes its specific mechanism, as it works by directly activating certain receptors in the eye. This particular action is what distinguishes it from other types of medicines that may also be used for pupil dilation.


Q: How long does it usually take to notice the therapeutic effects of Neofrin?

Official product information states that the onset of the primary effect, which is pupil dilation, typically begins relatively quickly. The effect is generally observed within 15 to 30 minutes after the drops are applied. The total duration of the effect can vary depending on the concentration used.


Q: Is the feeling of being tired or dizzy a frequent side effect of Neofrin?

Official documentation lists dizziness as a documented systemic adverse effect, which means it results from the drug being absorbed into the body. While it is not always listed among the most frequent, local side effects, the occurrence of dizziness may signal increased systemic absorption.


Q: What is the history of Neofrin's regulatory approval in the United States or Europe?

According to regulatory highlights, the ophthalmic solution containing Phenylephrine Hydrochloride has a long history. The drug was initially granted regulatory approval in the United States in 1939.


Q: Does Neofrin require any routine blood work or monitoring while taking it?

Official warnings describe that monitoring of blood pressure is advised for patients with pre-existing conditions like severe cardiac or endocrine diseases. The official label also advises caution and monitoring for pediatric patients who receive the higher 10% concentration solution.


Q: Is Neofrin available in a less expensive generic formulation?

Regulatory and commercial databases confirm that Neofrin is available in a generic formulation. The active ingredient, Phenylephrine Hydrochloride, is widely available from various manufacturers in addition to specific brand names.


Q: Do any official sources suggest a link between Neofrin and mood changes?

Official regulatory sources indicate that mood or mental changes have been reported as serious adverse reactions. These reported changes include symptoms such as confusion, anxiety, restlessness, or hyperactivity.


Q: What is the mechanism by which Neofrin is eliminated from the body?

According to pharmacokinetics sections in regulatory documents, the active ingredient is primarily broken down in the body by enzymes called Monoamine Oxidases. This metabolism occurs mainly in the intestines and liver. The final breakdown products are then eliminated from the body in the urine.

How should Neofrin be stored and disposed of?

The storage and disposal of Neofrin (phenylephrine ophthalmic solution) must adhere strictly to regulatory requirements to ensure product integrity and safety.


Storage Conditions

The product must be maintained at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). Storage must protect from light and excessive heat. It is explicitly stated: Do not freeze.


Container and Handling

Neofrin must be stored in its original container and the container must be kept tightly closed. For child safety, the medicine must be kept out of the sight and reach of children.


Disposal Instructions

Any unused, expired, or residual product must be disposed of in accordance with local regulations for pharmaceutical waste. The medication should not be discarded down the sink or drain to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Neofrin found in:

A-Z Index: